A Phase 3, Randomised, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Telitacicept in Combination with Standard of Care Therapy in Patients with Generalised Myasthenia Gravis

Grants and Contracts Details

StatusActive
Effective start/end date9/12/249/12/26

Funding

  • Pharmaceutical Research Associates: $11,931.00